Research programme: immunomodulators - PDS Biotechnology Corporation

Drug Profile

Research programme: immunomodulators - PDS Biotechnology Corporation

Alternative Names: PDS 102; PDS0102; PDS0102A; PDS0102B; PDS0103; PDS0204

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PDS Biotechnology Corporation
  • Developer National Cancer Institute (USA); PDS Biotechnology Corporation
  • Class Cancer vaccines; Influenza virus vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Influenza virus infections; Prostate cancer
  • No development reported Malignant melanoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (SC, Injection)
  • 09 Feb 2016 PDS Biotechnology establishes CRADA with National Institutes of Health for the development of Versamune® platform in Breast and Prostate cancer
  • 21 Feb 2014 Preclinical trials in Influenza virus infections in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top